These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 7908951)

  • 1. Benign intracranial hypertension associated with the withdrawal of a non-ergot dopamine agonist.
    Atkin SL; Masson EA; Blumhardt LD; White MC
    J Neurol Neurosurg Psychiatry; 1994 Mar; 57(3):371-2. PubMed ID: 7908951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients.
    Giusti M; Porcella E; Carraro A; Cuttica M; Valenti S; Giordano G
    J Endocrinol Invest; 1994 Jan; 17(1):51-7. PubMed ID: 7911813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Benign intracranial hypertension following the suspension of corticotherapy in a female patient previously operated on for Cushing's disease].
    Lucas A; Coll J; Salinas I; Sanmartí A
    Med Clin (Barc); 1991 Oct; 97(12):473. PubMed ID: 1753818
    [No Abstract]   [Full Text] [Related]  

  • 4. Prolactin bioassay and hyperprolactinemia.
    Peabody CA; Schultz PN; Warner MD; Worsley IG; Friesen HG; Samaan NA
    J Endocrinol Invest; 1992; 15(7):497-9. PubMed ID: 1360020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Benign intracranial hypertension resulting from corticosteroid withdrawal: case report].
    Saigusa K; Takei H; Shishido T; Ohki J; Naoe N; Ohno K
    No Shinkei Geka; 2002 Jan; 30(1):57-62. PubMed ID: 11806108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benign intracranial hypertension after topical steroid withdrawal.
    Fourie DT
    S Afr Med J; 1977 Aug; 52(8):301. PubMed ID: 897931
    [No Abstract]   [Full Text] [Related]  

  • 7. Pseudotumor cerebri associated with corticosteroid withdrawal in inflammatory bowel disease.
    Liu GT; Kay MD; Bienfang DC; Schatz NJ
    Am J Ophthalmol; 1994 Mar; 117(3):352-7. PubMed ID: 8129010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term treatment with a new non-ergot long-acting dopamine agonist, CV 205-502, in women with hyperprolactinaemia.
    Rasmussen C; Bergh T; Wide L; Brownell J
    Clin Endocrinol (Oxf); 1988 Sep; 29(3):271-9. PubMed ID: 2908030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quinagolide--a valuable treatment option for hyperprolactinaemia.
    Barlier A; Jaquet P
    Eur J Endocrinol; 2006 Feb; 154(2):187-95. PubMed ID: 16452531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pseudotumour Cerebri Syndrome in Two Children on Systemic Steroid Therapy for Uveitis.
    Curragh D; McLoone E
    Ocul Immunol Inflamm; 2018; 26(2):295-297. PubMed ID: 27599045
    [No Abstract]   [Full Text] [Related]  

  • 11. Prolactinoma-associated headache and dopamine agonist treatment.
    Kallestrup MM; Kasch H; Østerby T; Nielsen E; Jensen TS; Jørgensen JO
    Cephalalgia; 2014 Jun; 34(7):493-502. PubMed ID: 24351278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of CV205-502 in patients with hyperprolactinaemia intolerant and/or resistant to bromocriptine.
    Razzaq R; O'Halloran DJ; Beardwell CG; Shalet SM
    Horm Res; 1993; 39(5-6):218-22. PubMed ID: 7906243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pseudotumor cerebri following beta-human chorionic gonadotropin hormone treatment for undescended testicles.
    Haller JS; Meyer DR; Cromie W; Fagles N; Hayes S
    Neurology; 1993 Feb; 43(2):448-9. PubMed ID: 7679783
    [No Abstract]   [Full Text] [Related]  

  • 14. Pseudotumor cerebri associated with danazol withdrawal.
    Fanous M; Hamed LM; Margo CE
    JAMA; 1991 Sep; 266(9):1218-9. PubMed ID: 1870243
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of hyperprolactinemia treatment with the dopamine agonist quinagolide on endometriotic lesions in patients with endometriosis-associated hyperprolactinemia.
    Gómez R; Abad A; Delgado F; Tamarit S; Simón C; Pellicer A
    Fertil Steril; 2011 Mar; 95(3):882-8.e1. PubMed ID: 21055747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A case of pseudotumor cerebri probably due to the withdrawal of adrenal corticosteroid hormone].
    Ujihara M; Osawa M; Kobayashi I; Takemiya T; Maruyama S
    Nihon Naika Gakkai Zasshi; 1988 May; 77(5):661-6. PubMed ID: 3063762
    [No Abstract]   [Full Text] [Related]  

  • 17. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation.
    Webster J
    Drug Saf; 1996 Apr; 14(4):228-38. PubMed ID: 8713691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Benign intracranial hypertension during treatment with acetylsalicylic acid: presentation of 2 cases in children].
    Falcini F; Taccetti G; Montanelli F; Tafi L; Volpi M
    Pediatr Med Chir; 1989; 11(3):319-21. PubMed ID: 2594560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine function, psychiatric and clinical consequences in patients with macroprolactinomas after long-term treatment with the new non-ergot dopamine agonist CV205-502.
    Barnett PS; Palazidou E; Miell JP; Coskeran PB; Butler J; Dawson JM; Maccabe J; McGregor AM
    Q J Med; 1991 Nov; 81(295):891-906. PubMed ID: 1687293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine agonist withdrawal syndrome (DAWS) in a patient with a microprolactinoma.
    Demartini B; Ricciardi L; Ward A; Edwards MJ
    J Neurol Neurosurg Psychiatry; 2014 Apr; 85(4):471. PubMed ID: 24078717
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.